Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPN-817 OLE in Adults With Focal Onset Seizures
NCT07141329Phase 2Enrolling by invitation
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Huperzine A in focal onset seizure, sponsored by Supernus Pharmaceuticals, Inc. Primary endpoint: Incidence of treatment-emergent adverse events at 52 weeks. Started Jul 2025; status: enrolling by invitation.
02
Drugs
Huperzine A
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT07141329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07141329.